eOrdering the SYNVISC® Family of Products


From the MySynviscONE home page:

 Order online for next-day delivery* of SYNVISC and Synvisc-One®

 Manage your orders by PO#

 Ability for multiple clinics to manage inventory and assign kits to patients

*If order is submitted by 3 PM Eastern Time.


MySynviscONE eOrdering Offering

Product order history

 See all orders placed in the system and their current status

 Filter by PO#, status, clinic, and date range

 Click on a line to view details pertaining to that specific order

Product order details

 PO #, account #, and clinic

 Status, order and shipment dates

 Product and product quantity

 User who created the order


eOrdering from MySynviscONE account

Place online orders, view recent orders, track your order’s delivery status, and more with eOrdering from your MySynviscONE account


Alternative Ordering Options

 Call Sanofi directly at 1-888-3-SYNVISC (1-888-379-6847), Option #1, M–F, 8 AM–8 PM (ET), to place an order for your office.

 Contact your wholesaler. Place an order for your office through your wholesale supply house.

 Order through a Specialty Pharmacy. Learn more and download Specialty Pharmacy Order Forms.

 You can also fax a completed Credit Application Form PDF to 1-800-698-8979 .

 You can also place an order through your local representative.

Medicare patients
For Medicare-eligible patients, your clinic should consider purchasing and stocking SYNVISC/Synvisc-One in your office or the patient will be responsible for the full product price in most cases.


Order Synvisc-One® and SYNVISC®

Learn about the different ordering options and how to get next-day delivery with your MySynviscONE® account.

Order SYNVISC® (Hylan G‐F 20) and Synvisc‐ One® (Hylan G‐F 20)  icon.

MAT-US-2106837-v1.0-07/2021

MySynviscONE® Benefit Verification

Coordinate specialty pharmacy fulfillment online.

MAT-US-2106837-v1.0-07/2021

MySynviscONE®

Visit the MySynviscONE® section of the site for details and more.

Visit  MySynviscONE® to learn more about benefits.

MAT-US-2106837-v1.0-07/2021

INDICATION

SYNVISC® (hylan G-F 20) and Synvisc-One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One.

Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISC or Synvisc-One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.

The safety and efficacy of Synvisc-One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISC or Synvisc-One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children (≤21 years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.

FOR SYNVISC

In clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for SYNVISC

FOR SYNVISC-ONE

The most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for Synvisc-One

IMPORTANT SAFETY INFORMATION

Read More

IMPORTANT SAFETY INFORMATION

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One.

Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISC or Synvisc-One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.

The safety and efficacy of Synvisc-One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISC or Synvisc-One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children (≤21 years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.

FOR SYNVISC

In clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for SYNVISC

FOR SYNVISC-ONE

The most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for Synvisc-One